There are currently 116 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Glioblastoma participants are California, Ohio, New York and Pennsylvania.
Prospective Surgical Study on the Pattern of Electrical Activity in High Grade Glioma as a Predictor of Progression
NCT05565118
Recruiting
The purpose of this study is to test the safety and feasibility of recording brain activity within and around high-grade glioma tumors at the time of surgery. A small biopsy will be taken at the sites of the recordings.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: High Grade Glioma, Glioblastoma
Register for Updates
Glioblastoma Remote Monitoring and Care - Research Protocol
NCT06129760
Recruiting
The purpose of this research is to learn more about how what the Apple watch measures, in terms of walking data, heart rate, breathing rate, and sleep habits, relates to how participants feel. During the course of the treatment, the symptoms participants experience change, and whether the Apple watch can detect these changes. Ultimately, this knowledge is being used to design proactive tools and signatures that can predict complications or symptom changes before they happen.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Venous Thromboembolism, Seizures
Register for Updates
Sacituzumab Govitecan in Recurrent Glioblastoma
NCT04559230
Recruiting
This is an open-label single arm study. All patients will receive the investigational agent.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio +2 locations
Conditions: Glioblastoma
Register for Updates
Methimazole in Patients With Progressive Glioblastoma
NCT05607407
Recruiting
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Glioma
Register for Updates
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003
Recruiting
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Gl... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
06/21/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +104 locations
Conditions: Anaplastic Astrocytoma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioblastoma, Malignant Glioma, Anaplastic Astrocytoma, Not Otherwise Specified, Glioblastoma, Not Otherwise Specified
Register for Updates
A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma
NCT06388733
Recruiting
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are: Does niraparib improve progression-free survival (PFS) compared to TMZ? Does niraparib improve overall survival (OS) compared to TMZ? Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ. study drug (Niraparib) or comparat... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Ivy Brain Tumor Center, Phoenix, Arizona
Conditions: Glioblastoma, GBM, Brain Neoplasms, Adult, Malignant, Brain Tumor
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : Abemaciclib Temozolomide (temodar) Neratinib CC115 QBS10072S
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +11 locations
Conditions: Glioblastoma
Register for Updates
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
NCT04817254
Recruiting
Background: Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur. Researchers want to study people with newly diagnosed disease to learn more. Objective: To study people with newly diagnosed GBM or gliosarcoma to look at the changes in immune cells in the blood of those who take ipilimumab and nivolumab, along with temozolomide. Eligibility: Adults ages 18 and o... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioblastoma, Gliosarcoma, Malignant Glioma
Register for Updates
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
NCT03107780
Recruiting
This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +9 locations
Conditions: Glioblastoma, Gliosarcoma, Recurrent Glioblastoma, MGMT-Unmethylated Glioblastoma
Register for Updates
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
NCT03919071
Recruiting
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib... Read More
Gender:
All
Ages:
Between 12 months and 21 years
Trial Updated:
06/14/2024
Locations: Children's Hospital of Alabama, Birmingham, Alabama +126 locations
Conditions: Anaplastic Astrocytoma, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, Anaplastic Astrocytoma, Not Otherwise Specified
Register for Updates
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
NCT05902169
Recruiting
The brain is protected from any toxic or inflammatory molecule by the blood-brain barrier (BBB). This physical barrier is located at the level of the blood vessel walls. Because of these barrier properties, the blood vessels are also impermeable to the passage of therapeutic molecules from the blood to the brain. The development of effective treatments against glioblastoma is thus limited due to the BBB that prevents most drugs injected in the bloodstream from getting into brain tissue where the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Northwestern University, Chicago, Illinois +15 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, GBM
Register for Updates
Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
NCT02685605
Recruiting
INTRAGO II resembles a multicentric, prospective, randomized, 2-arm, open-label clinical phase III trial which tests if the median progression-free survival (PFS) of patients with newly diagnosed glioblastoma multiforme (GBM) can be improved by the addition of intraoperative radiotherapy (IORT) to standard radiochemotherapy.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
06/10/2024
Locations: Barrow Neurological Institute (SJHMC), Phoenix, Arizona +18 locations
Conditions: Glioblastoma
Register for Updates